PO.MCB08.02 · 分子与细胞生物学

Absence of somatic copy number alterations in non-neoplastic prostate epithelium

海报缩略图:Absence of somatic copy number alterations in non-neoplastic prostate epithelium
编号 1981 展板 7 时间 4/20 09:00–12:00 区域 Section 23 主讲 Ajay Vaghasia, BS
分会场 Genomic Drivers of Cancer Pathogenesis
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Ajay Vaghasia1, Levent Trabzonlu2, Anuj Gupta3, Ibrahim Kulac4, Busra Ozbek5, Jiayu Chen1, Qizhi Zheng3, Jessica L. Hicks3, Tracy Jones3, Roy Elias6, Alyza Skaist3, Jennifer Meyers3, Kornel Schuebel3, Christopher M. Heaphy7, Alan K. Meeker6, William G. Nelson8, Angelo Michael De Marzo3, Srinivasan Yegnasubramanian1

1Oncology, Johns Hopkins University School of Medicine, Baltimore, MD,2Pathology, University of Illinois Chicago, College of Medicine, Chicago, IL,3Johns Hopkins University School of Medicine, Baltimore, MD,4Johns Hopkins Univ., Baltimore, MD,5Kocaeli University, İzmit, Turkey,6Johns Hopkins University, Baltimore, MD,7Boston University, Boston, MA,8Sidney Kimmel Comprehensive Cancer Center, Cockeysville, MD

摘要 Abstract

Somatic copy number alterations (CNA) in cancer driver genes are a hallmark of human cancers, but have recently been reported in benign tissues in a handful of organ systems, including the prostate. However, these recent findings may be confounded by technical limitations and challenges in accurately ruling out cancer precursors such as intra-epithelial neoplastic lesions, particularly in frozen tissue. To address this, we used a panel of molecular markers to definitively distinguish benign glands from prostatic intra-epithelial neoplasia (PIN) and invasive cancer in frozen tissue sections, and used this as a guide for laser capture microdissection followed by whole genome sequencing to assess copy number alterations. Our analysis of 171 benign samples from 138 subjects revealed a complete absence of large copy number alterations (LCNA) in benign epithelium, including at key driver genes such as MYC, PTEN, RB1, and APC. In contrast, a significant fraction of PIN exhibited intermediate LCNA levels between benign and cancer. A post-hoc review of these copy number altered PIN lesions indicated that they would have been highly difficult to distinguish morphologically from benign prostate without the use of the panel of molecular markers. These results highlight the importance of rigorous molecular approaches for tissue diagnosis in frozen tissue and suggest that previous reports of CNA in benign prostate may reflect misidentified PIN.
利益披露 Disclosure
A. Vaghasia, None.. L. Trabzonlu, None.. A. Gupta, None.. J. Chen, None. W. G. Nelson, Armis Biosciences Other, Advisor to the Board of Directors. A. M. De Marzo, Merck Other, Consultant. Janssen ). Myraid ). S. Yegnasubramanian, Janssen ). Bristol-Myers Squibb/Celgene ).

在会议检索中打开